Targeted screening failures in neonates with sickle cell disease in metropolitan France from 2005 to 2017: Number of cases, failure circumstances and health at diagnosis

Remion, J; Pluchart, Claire

doi:10.1016/j.arcped.2019.10.006

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of reports on CF screening recently have been published: a cost-effectiveness analysis that compared four CF neonatal screening strategies with or without DNA testing to assess the value of combining cost effectiveness and ethics evaluation in health policy development (NBS laboratory protocol) [ 776 ]; studies analyzing inconclusive diagnoses after a screen-positive test (CFTR issues) including gene-sequencing and genetic counseling [ 777 , 778 , 779 , 780 ]; and review of a centralized tracking process to optimize the CF screening program [ 781 ]. Similarly, NBS for SCD, presently a targeted condition based on the geographical origins of both parents (malaria endemic areas) and a family history of SCD, has been the subject of several reports: screening and case management [ 782 ]; possible harmonization of HPLC result interpretations by applying multiple of median cutoff and ratios [ 783 ]; evaluation of POC testing [SickleSCAN™ (BioMedomics, Morrisville, NC USA)] [ 784 ]; and a study of targeted screening failures over the years (pushing for universal NBS for SCD—recommended by the Health Technical Agency since 2022) [ 785 ].…”

Section: Resultsmentioning

confidence: 99%

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)

Therrell,

Padilla,

Borrajo

et al. 2024

IJNS

View full text Add to dashboard Cite

Newborn bloodspot screening (NBS) began in the early 1960s based on the work of Dr. Robert “Bob” Guthrie in Buffalo, NY, USA. His development of a screening test for phenylketonuria on blood absorbed onto a special filter paper and transported to a remote testing laboratory began it all. Expansion of NBS to large numbers of asymptomatic congenital conditions flourishes in many settings while it has not yet been realized in others. The need for NBS as an efficient and effective public health prevention strategy that contributes to lowered morbidity and mortality wherever it is sustained is well known in the medical field but not necessarily by political policy makers. Acknowledging the value of national NBS reports published in 2007, the authors collaborated to create a worldwide NBS update in 2015. In a continuing attempt to review the progress of NBS globally, and to move towards a more harmonized and equitable screening system, we have updated our 2015 report with information available at the beginning of 2024. Reports on sub-Saharan Africa and the Caribbean, missing in 2015, have been included. Tables popular in the previous report have been updated with an eye towards harmonized comparisons. To emphasize areas needing attention globally, we have used regional tables containing similar listings of conditions screened, numbers of screening laboratories, and time at which specimen collection is recommended. Discussions are limited to bloodspot screening.

show abstract